Advanced search
Publication Cover
Ophthalmic Epidemiology Volume 22, 2015 - Issue 3: Trachoma
Submit an article Journal homepage
145
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Risk of Infection with Chlamydia trachomatis from Migrants to Communities Undergoing Mass Drug Administration for Trachoma Control

Sheila K. WestDana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA, Correspondence[email protected]
,
Beatriz E. MunozDana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA,
,
Harran MkochaKongwa Trachoma Project, Kongwa, Tanzania,
,
Charlotte GaydosInternational Chlamydia Laboratory, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA, and
&
Thomas QuinnInternational Chlamydia Laboratory, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA, and ;Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
Pages 170-175 | Received 30 Jan 2014, Accepted 30 Aug 2014, Published online: 09 Jul 2015

REFERENCES

  • Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol 2009;93(5):563–568
  • Assembly WH. Global elimination of blinding trachoma. 1998, WHA 51.11
  • WHO Working Group. Report of the eighth meeting of the WHO Alliance for the Global Elimination of blinding trachoma. Geneva: World Health Organization WHO/PBD/GET/04.2;2004. Available from: http://www.who.int/blindness/publications/GET_8_Report.pdf
  • Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004;351(19):1962–1971
  • West ES, Munoz B, Mkocha H, et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci 2005;46(1):83–87
  • World Health Organization. Third Global Scientific Meeting on Trachoma. 2010. Accessed May 9, 2013 from: http://www.who.int/blindness/publications/3RDGLOBALSCIENTIFICMEETINGONTRACHOMA.pdf
  • Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999;354(9179):630–635
  • Cajas-Monson LC, Mkocha H, Munoz B, et al. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania. PLoS Negl Trop Dis 2011;5(3):e978
  • Solomon AW, Holland MJ, Burton MJ, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet 2003;362(9379):198–204
  • West SK, Stare D, Mkocha H, et al. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma? Invest Ophthalmol Vis Sci 2011;52(8):6040–6042
  • Burton MJ, Holland MJ, Makalo P, et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet 2005;365(9467):1321–1328
  • Shah NA, House J, Lakew T, et al. Travel and implications for the elimination of trachoma in ethiopia. Ophthalmic Epidemiol 2010;17(2):113–117
  • Stare D, Harding-Esch E, Munoz B, et al. Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia. Ophthalmic Epidemiol 2011;18(1):20–29
  • Harding-Esch EM, Edwards T, Sillah A, et al. Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020? PLoS Negl Trop Dis 2009;3(12):e573
  • West SK, Bailey R, Munoz B, et al. A randomized trial of two coverage targets for mass treatment with azithromycin for trachoma. PLoS Negl Trop Dis 2013;7(8):e2415
  • Broman AT, Shum K, Munoz B, et al. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. Invest Ophthalmol Vis Sci 2006;47(1):99–104

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.